These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9836480)

  • 1. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
    Sandercock J; Parmar MK; Torri V
    Br J Cancer; 1998 Dec; 78(11):1471-8. PubMed ID: 9836480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
    J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gynecologic oncology group trials in ovarian carcinoma.
    Ozols RF
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.
    Sandercock J; Parmar MK; Torri V; Qian W
    Br J Cancer; 2002 Oct; 87(8):815-24. PubMed ID: 12373593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
    Atkins CD
    J Natl Cancer Inst; 2000 Sep; 92(17):1446-7. PubMed ID: 10974091
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
    Piccart MJ; Bertelsen K; Stuart G; Cassidy J; Mangioni C; Simonsen E; James K; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson R; Swenerton K; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lidvall B; Bacon M; Birt A; Andersen J; Zee B; Paul J; Pecorelli S; Baron B; McGuire W
    Int J Gynecol Cancer; 2003; 13 Suppl 2():144-8. PubMed ID: 14656271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132.
    Muggia FM
    Int J Gynecol Cancer; 2003; 13 Suppl 2():156-62. PubMed ID: 14656273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Canadian Intergroup trial (OV10 trial) and the US Gynaecologic Oncology Group trial (GOG 111).
    Swart AM; Parmar MK; Harper P; Colombo N; Torri V
    Int J Gynecol Cancer; 2004; 14(4):697; author reply 698. PubMed ID: 15304171
    [No Abstract]   [Full Text] [Related]  

  • 15. ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG. Gynaecologic Oncology Group.
    Piccart MJ; McGuire WP
    Lancet; 1999 Feb; 353(9152):587; author reply 588. PubMed ID: 10029002
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
    Ozols RF
    Cancer Invest; 2004; 22 Suppl 2():11-20. PubMed ID: 15573741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.
    Darcy KM; Brady WE; McBroom JW; Bell JG; Young RC; McGuire WP; Linnoila RI; Hendricks D; Bonome T; Farley JH;
    Gynecol Oncol; 2008 Dec; 111(3):487-95. PubMed ID: 18834621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.